Bone and joint disease
Conditions
Interventions
Half dose DVT prophylactic drug group:NA
Full dose DVT prophylactic drug group:NA
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Age 18-80 years old, gender is not limited; 2) Patients diagnosed with primary or secondary hip and knee diseases that have failed conservative treatment; 3) Patients who were assessed by the investigators to require initial unilateral total hip or total knee replacement surgery; 4) The subjects fully understand the benefits and risks of perioperative anticoagulation and are willing to participate in and sign the informed consent for the use of anticoagulation drugs.
Exclusion criteria
Exclusion criteria: 1) Body mass index (BMI)>35kg/m^2; 2) Patients with heart, lung and other important organ failure; 3) Abnormal liver and kidney function (ALT and AST> 1.5 times normal value, blood BUN>8.3 mmoll, blood Scr>115 umol/L); 4) Patients with diabetes and poorly controlled blood glucose levels who are judged by researchers to be at risk of infection; 5) Combined with consciousness disorder or mental illness; 6) Neuromuscular dysfunction affecting lower limb function; 7) Patients with severe coagulation disorder; 8) Combined with serious internal and surgical diseases or physical weakness, unable to tolerate surgery; 9) There is an active infection in the body (systemic or local infection lesions); 10) Preoperative inflammatory indicators for non-inflammatory diseases were more than 2 times the upper limit of normal; 11) Preoperative inflammatory indicators for inflammatory diseases exceed the upper limit of normal by 3 times; 12) Have serious osteoporosis, metabolic bone disease, radiation bone disease, tumor; 13) Women with family planning, lactation and pregnancy throughout the clinical study period; 14) Participants who have participated in other clinical trials within 3 months; 15) Participants who are not considered suitable to participate in this clinical trial for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| deep venous thrombosis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total blood loss;hospital stays;womac index; | — |
Countries
China
Contacts
Public ContactWang Haoyang
West China Hospital of Sichuan University
Outcome results
None listed